Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (28) 28
mice (19) 19
biochemistry & molecular biology (16) 16
humans (16) 16
index medicus (14) 14
oncology (13) 13
female (10) 10
3t3 cells (9) 9
male (9) 9
expression (8) 8
kinetics (8) 8
phosphorylation (8) 8
rats (8) 8
signal transduction - drug effects (8) 8
cancer (7) 7
insulin (7) 7
signal transduction (7) 7
cell line, tumor (6) 6
gene amplification (6) 6
growth hormone - pharmacology (6) 6
mutations (6) 6
piperazines - pharmacology (6) 6
pyrazoles - pharmacology (6) 6
benzamides - pharmacology (5) 5
chemotherapy (5) 5
gtp-binding proteins - metabolism (5) 5
lung cancer (5) 5
middle aged (5) 5
adipose tissue - metabolism (4) 4
aged (4) 4
antineoplastic agents - pharmacology (4) 4
biomarkers (4) 4
biophysics (4) 4
calcium-calmodulin-dependent protein kinases - metabolism (4) 4
cell differentiation - drug effects (4) 4
clinical trials (4) 4
enzyme activation (4) 4
enzyme inhibitors - pharmacology (4) 4
insulin - pharmacology (4) 4
isoproterenol - pharmacology (4) 4
map kinase (4) 4
patients (4) 4
protein-tyrosine kinases - metabolism (4) 4
receptors, fibroblast growth factor - antagonists & inhibitors (4) 4
substrate specificity (4) 4
tumors (4) 4
tyrosine phosphorylation (4) 4
activation (3) 3
adenylyl cyclases - metabolism (3) 3
adipocytes - cytology (3) 3
adipose conversion (3) 3
adult (3) 3
amplification (3) 3
analysis (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
article (3) 3
breast-cancer (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
cell biology (3) 3
cell differentiation - physiology (3) 3
cell membrane - metabolism (3) 3
cell proliferation - drug effects (3) 3
chemistry, medicinal (3) 3
colforsin - pharmacology (3) 3
cyclic amp - pharmacology (3) 3
cyclic-amp (3) 3
differentiation (3) 3
factor-i (3) 3
gene expression profiling (3) 3
growth hormone - physiology (3) 3
hypertension (3) 3
inhibitor (3) 3
lung cancer, non-small cell (3) 3
lung neoplasms - genetics (3) 3
medical prognosis (3) 3
medical research (3) 3
mice, nude (3) 3
models, molecular (3) 3
molecular targeted therapy (3) 3
mutation (3) 3
neoplasm metastasis (3) 3
non-small cell lung carcinoma (3) 3
oligonucleotides, antisense - pharmacology (3) 3
pertussis toxin (3) 3
receptor, fibroblast growth factor, type 1 - genetics (3) 3
receptor, insulin - metabolism (3) 3
sensitivity (3) 3
treatment outcome (3) 3
tyrosine - metabolism (3) 3
xenograft model antitumor assays (3) 3
1-methyl-3-isobutylxanthine - pharmacology (2) 2
11-beta-hydroxysteroid dehydrogenase type 1 - antagonists & inhibitors (2) 2
11-beta-hydroxysteroid dehydrogenase type 1 - metabolism (2) 2
3t3-f442a cell (2) 2
3t3-l1 cells (2) 2
adenylate-cyclase (2) 2
adipocytes (2) 2
adipocytes - drug effects (2) 2
adipocytes - enzymology (2) 2
adipose tissue - drug effects (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial
by Jänne, Pasi A and van den Heuvel, Michel M and Barlesi, Fabrice and Cobo, Manuel and Mazieres, Julien and Crinò, Lucio and Orlov, Sergey and Blackhall, Fiona and Wolf, Juergen and Garrido, Pilar and Poltoratskiy, Artem and Mariani, Gabriella and Ghiorghiu, Dana and Kilgour, Elaine and Smith, Paul and Kohlmann, Alexander and Carlile, David J and Lawrence, David and Bowen, Karin and Vansteenkiste, Johan
JAMA, ISSN 0098-7484, 05/2017, Volume 317, Issue 18, pp. 1844 - 1853
IMPORTANCE: There are no specifically approved targeted therapies for the most common genomically defined subset of non–small cell lung cancer (NSCLC),... 
MEDICINE, GENERAL & INTERNAL | PHASE-II | MULTICENTER | MUTATIONS | AZD6244 ARRY-142886 | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Disease Progression | Disease-Free Survival | Taxoids - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Benzimidazoles - adverse effects | Taxoids - adverse effects | Drugs | Care and treatment | Cancer patients | Docetaxel | Dosage and administration | Diagnosis | Lung cancer, Non-small cell | Health aspects | Inhibitor drugs | Cell survival | Lung cancer | Clinical trials | Non-small cell lung carcinoma | MAP kinase | Patients | Survival | K-Ras protein | Side effects | Randomization | Protein kinase | Drug therapy | Cancer | Original Investigation | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Will liquid biopsies improve outcomes for patients with small-cell lung cancer?
by Blackhall, Fiona and Frese, Kristopher K and Simpson, Kathryn and Kilgour, Elaine and Brady, Ged and Dive, Caroline
The Lancet Oncology, ISSN 1470-2045, 09/2018, Volume 19, Issue 9, pp. e470 - e481
Small-cell lung cancer (SCLC) is an aggressive tumour that seeds metastases early with dismal outcomes. As expected from a disease that is closely associated... 
ORGANOID CULTURES | HETEROGENEITY | DRUG-SENSITIVITY | CIRCULATING TUMOR-CELLS | ONCOLOGY | PD-L1 EXPRESSION | MOUSE | FREE DNA | PROGRESSION-FREE | OPEN-LABEL | NIVOLUMAB PLUS IPILIMUMAB | Lung Neoplasms - genetics | Predictive Value of Tests | Liquid Biopsy | Circulating Tumor DNA - genetics | Neoplastic Cells, Circulating - pathology | Humans | Lung Neoplasms - pathology | Neoplastic Cells, Circulating - chemistry | Small Cell Lung Carcinoma - genetics | Molecular Targeted Therapy | Small Cell Lung Carcinoma - blood | Patient Selection | Small Cell Lung Carcinoma - secondary | Animals | Clinical Decision-Making | Small Cell Lung Carcinoma - diagnosis | Lung Neoplasms - blood | Circulating Tumor DNA - blood | Lung Neoplasms - diagnosis | Neoplasm Staging | Precision Medicine | Chemotherapy | Medical examination | Analysis | Patient outcomes | Research institutes | Metastasis | Blood | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer
by Brooks, A. Nigel and Kilgour, Elaine and Smith, Paul D
Clinical Cancer Research, ISSN 1078-0432, 04/2012, Volume 18, Issue 7, pp. 1855 - 1862
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling axis plays an important role in normal organ, vascular, and skeletal... 
CELL LUNG-CANCER | MULTIPLE-MYELOMA | FACTOR FAMILY | HEPATOCELLULAR-CARCINOMA | SELECTIVE INHIBITOR | ONCOLOGY | ANTITUMOR-ACTIVITY | TUMOR-GROWTH | RECEPTOR TYROSINE KINASE | ACTIVATING MUTATIONS | FGF RECEPTOR | Neoplasms - metabolism | Humans | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Neoplasms - blood supply | Clinical Trials as Topic | Neoplasms - drug therapy | Fibroblast Growth Factors - metabolism | Models, Biological | Protein Kinase Inhibitors - therapeutic use | Receptors, Fibroblast Growth Factor - metabolism | Neovascularization, Pathologic - physiopathology | Neovascularization, Pathologic - prevention & control | Signal Transduction - physiology | Neovascularization, Pathologic - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’
by Conway, Alicia-Marie and Mitchell, Claire and Kilgour, Elaine and Brady, Gerard and Dive, Caroline and Cook, Natalie
British Journal of Cancer, ISSN 0007-0920, 01/2019, Volume 120, Issue 2, pp. 141 - 153
Cancers of Unknown Primary (CUP) comprise a heterogeneous clinical entity of confirmed metastatic cancer where the primary site of origin is undetectable. It... 
LUNG-CANCER | CIRCULATING TUMOR-CELLS | EARLY DISSEMINATION | PAN-CANCER | ONCOLOGY | PRIMARY SITE | TREATMENT OUTCOMES | COLORECTAL-CANCER | GENE-EXPRESSION | FREE DNA | PRIMARY ORIGIN | Carcinogens | Historical account | Biopsy | Medical prognosis | Biological evolution | Biomarkers | Biology | Patients | Carcinogenesis | Tumors | Cancer | Metastases | Index Medicus | Tumour biomarkers | Review | Cancer of unknown primary | Cancer genomics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text A phase Ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers
by Paik, Paul K and Shen, Ronglai and Berger, Michael F and Ferry, David and Soria, Jean-Charles and Mathewson, Alastair and Rooney, Claire and Smith, Neil R and Cullberg, Marie and Kilgour, Elaine and Landers, Donal and Frewer, Paul and Brooks, Nigel and Andre, Fabrice
Clinical Cancer Research, ISSN 1078-0432, 09/2017, Volume 23, Issue 18, pp. 5366 - 5373
Purpose: Squamous cell lung cancers (SQCLC) account for 25% of all NSCLCs, yet the prognosis of these patients is poor and treatment options are limited.... 
ACTIVATION | ONCOLOGY | THERAPEUTIC TARGET | FGFR1 | Immunohistochemistry | Pharmacodynamics | Lung cancer | Pharmacology | Gene expression | Patients | Gene sequencing | Anticancer properties | Amplification | Gene amplification | Experimental design | Safety engineering | Medical prognosis | Cell lines | Chromosome 8 | Xenografts | Antitumor activity | Pharmacokinetics | Fibroblast growth factor receptor 1 | Tumors | Cancer | Fibroblast growth factor receptors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family
by Gavine, Paul R and Mooney, Lorraine and Kilgour, Elaine and Thomas, Andrew P and Al-Kadhimi, Katherine and Beck, Sarah and Rooney, Claire and Coleman, Tanya and Baker, Dawn and Mellor, Martine J and Brooks, A. Nigel and Klinowska, Teresa
Cancer Research, ISSN 0008-5472, 04/2012, Volume 72, Issue 8, pp. 2045 - 2056
The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance. Several small-molecule FGF receptor (FGFR)... 
MULTIPLE-MYELOMA | APOPTOSIS | TRANSLOCATION | ONCOLOGY | IN-VIVO | RESISTANCE | AZD2171 | MUTATIONS | EXPRESSION | CARCINOMA | CANCER CELL-LINES | Protein Kinase Inhibitors - pharmacokinetics | Benzamides - pharmacokinetics | Humans | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Piperazines - pharmacology | Animals | Mice, Nude | Cell Line, Tumor | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Piperazines - pharmacokinetics | Pyrazoles - pharmacokinetics | Neoplasms, Experimental - drug therapy | Pyrazoles - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Targeting Non-Small Cell Lung Cancer Cells by Dual Inhibition of the Insulin Receptor and the Insulin-Like Growth Factor-1 Receptor
by Vincent, Emma E and Elder, Douglas J. E and Curwen, Jon and Kilgour, Elaine and Hers, Ingeborg and Tavaré, Jeremy M
PLoS ONE, ISSN 1932-6203, 06/2013, Volume 8, Issue 6, p. e66963
Phase III trials of the anti-insulin-like growth factor-1 receptor (IGF1R) antibody figitumumab in non-small cell lung cancer (NSCLC) patients have been... 
IGF-I | HUMAN-BREAST-CANCER | PLASMA-LEVELS | CLINICAL DEVELOPMENT | HYBRID RECEPTORS | MULTIDISCIPLINARY SCIENCES | PROSTATE-CANCER | BINDING PROTEIN-3 | MONOCLONAL-ANTIBODIES | EXPRESSION | LINES | Cell Survival - drug effects | Receptor, IGF Type 1 - metabolism | Receptor, IGF Type 1 - antagonists & inhibitors | Antibodies, Monoclonal - pharmacology | Humans | Lung Neoplasms - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | Pyrimidines - pharmacology | Molecular Targeted Therapy | Receptor, Insulin - antagonists & inhibitors | Isoxazoles - pharmacology | Signal Transduction - drug effects | Cell Line, Tumor | Receptor, Insulin - metabolism | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Viral antibodies | Tyrosine | Prevention | Analysis | Antibodies | Lung cancer, Small cell | Lung cancer, Non-small cell | Phosphotransferases | Cancer | Cell proliferation | Phosphorylation | Insulin-like growth factor I | Lung cancer | Clinical trials | Homology | AKT protein | Biochemistry | Insulin-like growth factors | Kinases | Signal transduction | Rodents | Inhibition | Insulin-like growth factor II | Protein-tyrosine kinase | Immunoglobulins | Medical treatment | Non-small cell lung carcinoma | Metabolism | Insulin | Studies | Signaling | Chemotherapy | Inhibitors | Cell lines | Ligands | Prostate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial
by Pearson, Alex and Smyth, Elizabeth and Babina, Irina S and Herrera-Abreu, Maria Teresa and Tarazona, Noelia and Peckitt, Clare and Kilgour, Elaine and Smith, Neil R and Geh, Catherine and Rooney, Claire and Cutts, Ros and Campbell, James and Ning, Jian and Fenwick, Kerry and Swain, Amanda and Brown, Gina and Chua, Sue and Thomas, Anne and Johnston, Stephen R. D and Ajaz, Mazhar and Sumpter, Katherine and Gillbanks, Angela and Watkins, David and Chau, Ian and Popat, Sanjay and Cunningham, David and Turner, Nicholas C
Cancer Discovery, ISSN 2159-8274, 08/2016, Volume 6, Issue 8, pp. 838 - 851
FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical... 
BREAST-CANCER | ONCOLOGY | HER2 | EXPRESSION | CHEMOTHERAPY | GROWTH | Phosphorylation | Humans | Male | Tomography, X-Ray Computed | Gene Expression Profiling | Phosphatidylinositol 3-Kinases - metabolism | Positron-Emission Tomography | Clonal Evolution - genetics | Molecular Targeted Therapy | Receptors, Fibroblast Growth Factor - genetics | Female | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Pyrazoles - pharmacology | Stomach Neoplasms - genetics | Stomach Neoplasms - diagnosis | Tachykinins - metabolism | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Piperazines - pharmacology | Xenograft Model Antitumor Assays | Animals | Breast Neoplasms - genetics | Gene Amplification | Signal Transduction - drug effects | Cell Line, Tumor | Breast Neoplasms - diagnosis | Mice
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547
by Xie, Liang and Su, Xinying and Zhang, Lin and Yin, Xiaolu and Tang, Lili and Zhang, Xiuhua and Xu, Yanping and Gao, Zeren and Liu, Kunji and Zhou, Minhua and Gao, Beirong and Shen, Danping and Zhang, Lianhai and Ji, Afu and Gavine, Paul R and Zhang, Jingchuan and Kilgour, Elaine and Zhang, Xiaolin and Ji, Qunsheng
Clinical Cancer Research, ISSN 1078-0432, 05/2013, Volume 19, Issue 9, pp. 2572 - 2583
Purpose: FGFR gene aberrations are associated with tumor growth and survival. We explored the role of FGFR2 amplification in gastric cancer and the therapeutic... 
POTENT | THERAPY | TRASTUZUMAB | ONCOLOGY | GROWTH-FACTOR RECEPTOR-2 | PATTERNS | SOMATIC MUTATIONS | BREAST | FAMILY | Piperazines - administration & dosage | RNA, Small Interfering - genetics | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Humans | Middle Aged | Stomach Neoplasms - metabolism | Male | Case-Control Studies | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Cisplatin - administration & dosage | Gene Knockdown Techniques | Young Adult | Benzamides - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Inhibitory Concentration 50 | Adult | Camptothecin - administration & dosage | Female | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Camptothecin - analogs & derivatives | Stomach Neoplasms - genetics | Signal Transduction | Treatment Outcome | Stomach Neoplasms - drug therapy | Drug Synergism | Xenograft Model Antitumor Assays | Taxoids - administration & dosage | Pyrazoles - administration & dosage | Animals | Gene Amplification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Adolescent | Cell Line, Tumor | Aged | Mice | Mice, Inbred BALB C | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Characterization of FGFR1 locus in sqNSCLC reveals a broad and heterogeneous amplicon
by Rooney, Claire and Geh, Catherine and Williams, Victoria and Heuckmann, Johannes M and Menon, Roopika and Schneider, Petra and Al-Kadhimi, Katherine and Dymond, Michael and Smith, Neil R and Baker, Dawn and French, Tim and Smith, Paul D and Harrington, Elizabeth A and Barrett, J. Carl and Kilgour, Elaine
PLoS ONE, ISSN 1932-6203, 02/2016, Volume 11, Issue 2, p. e0149628
FGFR1 amplification occurs in similar to 20% of sqNSCLC and trials with FGFR inhibitors have selected FGFR1 amplified patients by FISH. Lung cancer cell lines... 
CELL LUNG-CANCER | SURVIVAL | MESSENGER-RNA | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | HUMAN BREAST-CANCER | EXPRESSION | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Reproducibility of Results | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Gene Expression Regulation, Neoplastic | In Situ Hybridization, Fluorescence | Cell Line, Tumor - drug effects | Chromosomes, Human, Pair 8 | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Piperazines - pharmacology | Gene Amplification | Comparative Genomic Hybridization | Benzamides - pharmacology | Cell Proliferation - drug effects | Carcinoma, Non-Small-Cell Lung - drug therapy | Molecular Targeted Therapy - methods | Pyrazoles - pharmacology | Physiological aspects | Development and progression | Genetic aspects | Research | Lung cancer, Non-small cell | Fibroblast growth factor receptors | Copy number | Genes | Lung cancer | Clinical trials | Oncology | Statistical methods | Kinases | Cell growth | Animal tissues | Fibroblast growth factor receptor 1 | Medical research | Statistical analysis | Non-small cell lung carcinoma | Breast cancer | Tumor cell lines | Gene expression | Ribonucleic acid--RNA | Amplification | Sensitivity | Gene amplification | Inhibitors | Chromosome 8 | Biomarkers | Protein expression | Mutation | Tumors | RNA | Ribonucleic acid
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer
by Powles, Thomas and Kilgour, Elaine and Mather, Richard and Galer, Anne and Arkenau, Hendrik-Tobias and Farnsworth, Andrew and Wilde, Jonathan and Ratnayake, Jayantha and Landers, Donal
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. TPS4577 - TPS4577
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Complexity of FGFR signalling in metastatic urothelial cancer
by Rodriguez-Vida, Alejo and Saggese, Matilde and Hughes, Simon and Rudman, Sarah and Chowdhury, Simon and Smith, Neil R and Lawrence, Peter and Rooney, Claire and Dougherty, Brian and Landers, Donal and Kilgour, Elaine and Arkenau, Hendrik-Tobias
Journal of Hematology and Oncology, ISSN 1756-8722, 10/2015, Volume 8, Issue 1, p. 119
Background: Urothelial cancers (UC) are the fourth most common tumours worldwide after prostate (or breast), lung and colorectal cancer. Despite recent... 
AZD4547 | Urothelial cancer | Biomarker | FGFR | BLADDER-CANCER | GUIDELINES | AMPLIFICATION | ONCOLOGY | PREDICT | SENSITIVE FGFR2 | PROTEIN EXPRESSION | MUTATIONS | HEMATOLOGY | CARCINOMA | Immunohistochemistry | Receptor, Epidermal Growth Factor - genetics | Pyrazoles - therapeutic use | Humans | Middle Aged | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Kidney Pelvis - metabolism | Male | Antineoplastic Agents - therapeutic use | Ureteral Neoplasms - metabolism | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Receptor, Fibroblast Growth Factor, Type 3 - metabolism | Ureteral Neoplasms - drug therapy | Neoplasm Metastasis | Receptor, Epidermal Growth Factor - metabolism | Benzamides - therapeutic use | Urinary Bladder Neoplasms - genetics | Gene Expression Regulation, Neoplastic - drug effects | Urinary Bladder Neoplasms - metabolism | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Ureteral Neoplasms - genetics | Kidney Pelvis - pathology | In Situ Hybridization, Fluorescence | Piperazines - therapeutic use | Signal Transduction - genetics | Urinary Bladder Neoplasms - drug therapy | Signal Transduction - drug effects | Medical research | Care and treatment | Chemotherapy | Analysis | Colorectal cancer | Medicine, Experimental | Development and progression | Fibroblast growth factors | Metastasis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
by Carvajal, Richard D and Piperno-Neumann, Sophie and Kapiteijn, Ellen and Chapman, Paul B and Frank, Stephen and Joshua, Anthony M and Piulats, Josep M and Wolter, Pascal and Cocquyt, Veronique and Chmielowski, Bartosz and Evans, T.R. Jeffry and Gastaud, Lauris and Linette, Gerald and Berking, Carola and Schachter, Jacob and Rodrigues, Manuel J and Shoushtari, Alexander N and Clemett, Delyth and Ghiorghiu, Dana and Mariani, Gabriella and Spratt, Shirley and Lovick, Susan and Barker, Peter and Kilgour, Elaine and Lai, Zhongwu and Schwartz, Gary K and Nathan, Paul
Journal of Clinical Oncology, ISSN 0732-183X, 04/2018, Volume 36, Issue 12, pp. 1232 - 1239
PurposeUveal melanoma is the most common primary intraocular malignancy in adults with no effective systemic treatment option in the metastatic setting.... 
ONCOLOGY | GNAQ | GROWTH | MUTATIONS | AZD6244 ARRY-142886 | INHIBITOR | CANCER | Dacarbazine - administration & dosage | Dacarbazine - adverse effects | Uveal Neoplasms - pathology | Double-Blind Method | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Melanoma - pathology | Uveal Neoplasms - drug therapy | Neoplasm Metastasis | Benzimidazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Progression-Free Survival | Placebos | Adult | Female | Aged | Benzimidazoles - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Abstract 5095: Development of a pharmacodynamic biomarker assay for AZD4785, an antisense oligonucleotide targeting KRAS
by Rooney, Claire and Ross, Sarah and Staniszewska, Anna and Lennarz, Sabine and Kilgour, Elaine and Revenko, Alexey S and Macleod, A. Robert and Pierce, Andrew and Lyne, Paul D and Barrett, J. Carl and Harrington, Elizabeth A
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 13 Supplement, pp. 5095 - 5095
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models
by Zhang, Jingchuan and Zhang, Lin and Su, Xinying and Li, Ming and Xie, Liang and Malchers, Florian and Fan, ShuQiong and Yin, XiaoLu and Xu, YanPing and Liu, Kunji and Dong, Zhengwei and Zhu, Guanshan and Qian, Ziliang and Tang, Lili and Zhan, Ping and Ji, Qunsheng and Kilgour, Elaine and Smith, Paul D and Brooks, A. Nigel and Thomas, Roman K and Gavine, Paul R
Clinical Cancer Research, ISSN 1078-0432, 12/2012, Volume 18, Issue 24, pp. 6658 - 6667
Purpose: To investigate the incidence of FGFR1 amplification in Chinese non-small cell lung cancer (NSCLC) and to preclinically test the hypothesis that the... 
BREAST-CANCER | ONCOLOGY | GROWTH-FACTOR RECEPTOR-2 | MUTATIONS | INHIBITOR | EXPRESSION | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Benzamides - therapeutic use | Female | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Pyrazoles - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Piperazines - therapeutic use | Piperazines - pharmacology | Xenograft Model Antitumor Assays | Animals | Gene Amplification | Signal Transduction - drug effects | Mice, Nude | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text A Phase 1b Open Label Multicentre Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
by Paik, Paul K and Shen, Ronglai and Berger, Michael F and Ferry, David and Soria, Jean-Charles and Mathewson, Alastair and Rooney, Claire and Smith, Neil R and Cullberg, Marie and Kilgour, Elaine and Landers, Donal and Frewer, Paul and Brooks, Nigel and Andre, Fabrice
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 9/2017, Volume 23, Issue 18, pp. 5366 - 5373
AZD4547 | squamous lung cancer | FGFR1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer
by Arkenau, Hendrik-Tobias and Saggese, Matilde and Hollebecque, Antoine and Mathewson, Alastair and Lemech, Charlotte Rose and Landers, Donal and Frewer, Paul and Kilgour, Elaine and Brooks, Nigel
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. 2620 - 2620
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study
by Bang, Yung-Jue and Van Cutsem, Eric and Mansoor, Wasat and Petty, Russell D and Chao, Yee and Cunningham, David and Ferry, David and Landers, Donal and Stockman, Paul and Smith, Neil R and Geh, Catherine and Kilgour, Elaine
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. 4014 - 4014
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights